{
  "docId": "019de074-3cc2-7451-b551-f16094d96b35",
  "docSlug": "3309edf11a92b656dd98b92129b54a19",
  "documentTitle": "Recursion Pharmaceuticals | Investor Day Presentation Deck | 143 slides",
  "authorId": "recursion-pharmaceuticals",
  "authorName": "Recursion Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 102,
  "pageCount": 120,
  "prevPage": 101,
  "nextPage": 103,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Slide 102 from a presentation deck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-3cc2-7451-b551-f16094d96b35/102",
  "deckHref": "/decks/019de074-3cc2-7451-b551-f16094d96b35",
  "deckJsonHref": "/decks/019de074-3cc2-7451-b551-f16094d96b35.json",
  "deckAnchorHref": "/decks/019de074-3cc2-7451-b551-f16094d96b35#slide-102",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.07,
        "y": 0.6
      },
      "kind": "chart",
      "text": "Progression-Free Survival",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3034ecf1-5ab7-4afb-a541-c3b85fc7b71f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.05,
        "x": 0.55,
        "y": 0.28
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8825ecfb-f99d-4c77-9a09-8c1d1b8b7288",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.55,
        "y": 0.62
      },
      "kind": "list",
      "text": "... with a drug-like profile\nEstablished and scalable API manufacturing process\nMultiple cGMP batches of 10mg and 50mg tablets have been manufactured\nExcellent long-term stability",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "603a2c5b-c212-40fe-9aed-167ede489840",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "list",
      "text": "Evaluable Patients: CNS Solid Tumors: NF2 N=5; Non-CNS Solid Tumors: N=10\nPFS: CNS solid tumors = 9.1 months; Non-CNS solid tumors = 1.7 months\nBest overall response = SD in 8/15 patients (53%; 95% CI 26.6–78.7)\nLongest duration of follow-up without progression: > 27 months (N=1)\nMost common AEs: cytopenia, fatigue, nausea",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98f5da86-3d52-4a5b-bbc9-4d3bae6b7f40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.55,
        "y": 0.22
      },
      "kind": "list",
      "text": "Well understood clinical safety ...\nMultiple investigator-initiated studies in oncology indications\nLengthy human clinical exposure in NF2 – multiple patients on drug for several years\nWell-characterized side effect profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8fb6164-6262-4967-90a1-8c5576c0a5b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Further Confidence : Prior Studies Suggestive of Potential Therapeutic Benefit",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "120954dd-036b-4731-9dd3-76736324520d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 15,
      "beatId": "136386a5-6141-40a4-88e2-1f9e9bd0026c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Recursion's solution, including its technology, approach, and progress in drug discovery.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 120,
      "from": 15,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "781e998b-dc37-46ea-ab12-3271a3953fda",
      "evidence": "The document presents Recursion's solution, including its technology, approach, and progress in drug discovery.",
      "position": 1,
      "objective": "How can Recursion's technology and approach improve drug discovery outcomes?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}